AllerGenis

About AllerGenis

AllerGenis, established in 2017, is a precision diagnostics company focused on addressing the inaccuracies of traditional food allergy testing. The company was founded as a result of a collaboration between Genisphere and Dr. Hugh Sampson of the Icahn School of Medicine at Mount Sinai. CEO and board member, Jim Garner, has over three decades of experience in the life sciences sector, having held executive roles at companies like Integrated Diagnostics and UnitedHealth Group before leading the establishment of AllerGenis.

The company targets a significant market inefficiency where current diagnostics, such as skin prick and serologic tests, can have false positive rates as high as 60%. AllerGenis operates in the food allergy diagnostics market, serving clinicians, allergists, and directly to consumers via a partnership with the telemedicine platform, LifeMD. Revenue is generated through the sale of its diagnostic tests and collaborations with pharmaceutical companies, which use AllerGenis' biomarkers in clinical trials for new allergy treatments.

AllerGenis' core product is a blood test that utilizes a proprietary epitope mapping platform. This technology, developed over 20 years by Dr. Sampson, subdivides allergenic proteins into smaller components called epitopes to measure a patient's antibody reactivity with high precision. The output creates a unique 'epitope signature' for each patient. Its first commercial product, the VeriMap™ Peanut Diagnostic, demonstrates up to 93% accuracy in concordance with the results of an oral food challenge (OFC), the clinical gold standard, but without the associated risks or long waiting times. This provides a more definitive diagnosis and can determine a patient's specific tolerance threshold, offering clear guidance for managing their allergy. The company is amassing a large database of these patient signatures, using machine learning to derive further clinical insights. Following its initial success with the peanut assay, AllerGenis is developing a pipeline of tests for other common allergens, including milk, egg, and tree nuts.